Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

October 31, 2012

Conditions
Alzheimer's Disease
Interventions
DRUG

tideglusib

1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.

DRUG

tideglusib

1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension

DRUG

tideglusib

500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.

DRUG

Placebo

Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.

Trial Locations (6)

Unknown

Leuven and 4 Additional Cities

Turku and 3 Additional Cities

Paris and 10 Additional Cities

Freiburg and 5 Additional Cities

Madrid and 7 Additional Cities

London and 11 Additional Cities

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Noscira SA

INDUSTRY